The Magazine for Sleep Professionals
Saturday, April 18, 2026
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with […]
Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy Harmony Biosciences, LLC (Harmony) recently presented new data on pitolisant at the 7th International Symposium on Narcolepsy in Beverly, MA. Pitolisant is an investigational product that has […]
On the weekend of March 9 – 11, 2018, Project Sleep invites you to join the fourth annual international Sleep In (#SleepIn2018) to raise awareness about sleep health and sleep disorders during Sleep Awareness Week. Project Sleep is a 501(c)(3) non-profit organization that aims to educate and empower individuals using […]
